Research programme: small molecule therapeutics - Elastin Bioscience
Latest Information Update: 10 Jun 2024
At a glance
- Originator Elastin Biosciences
- Class Small molecules; Vascular disorder therapies
- Mechanism of Action Elastin stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Abdominal aortic aneurysm; Neurodegenerative disorders
Most Recent Events
- 03 Jun 2024 Adverse events and pharmacodynamics data from a preclinical trial in Abdominal aortic aneurysm and Williams syndrome released by Elastin Biosciences
- 03 Jun 2024 Elastin Biosciences plans IND-enabling trial for Williams Syndrome and Abdominal aortic aneurysm in 2024
- 03 Jun 2024 Elastin Biosciences plans phase I clinical trial for Williams Syndrome and Abdominal aortic aneurysm by January 2026